quinazolines has been researched along with cabozantinib in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 31 (83.78) | 24.3611 |
| 2020's | 6 (16.22) | 2.80 |
| Authors | Studies |
|---|---|
| Takami, HE | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Postel-Vinay, S; Schlumberger, M; Soria, JC | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Cabanillas, ME; Hu, MI; Jimenez, C | 1 |
| Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
| Jarzab, B; Krajewska, J | 1 |
| Fassnacht, M; Kreissl, MC; Mueller, SP | 1 |
| Covell, LL; Ganti, AK | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Hadoux, J; Pacini, F; Schlumberger, M; Tuttle, RM | 1 |
| Ali, SM; Busaidy, NL; Chmielecki, J; Elvin, JA; Erlich, RL; Heilmann, AM; Khan, SA; Lipson, D; Miller, VA; Murthy, R; Nangia, C; Ross, JS; Shah, MH; Sherman, SI; Stephens, PJ; Subbiah, I; Subbiah, V; Sun, JX; Vergilio, JA; Wang, K; Yelensky, R | 1 |
| Chen, AY; Ernani, V; Kumar, M; Owonikoko, TK | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Boyun, S; Hongyi, H; Jiang, L; Jianye, Y; Ping, T; Shiying, W; Wanjun, Z | 1 |
| Hong, SK; Park, JI; Starenki, D; Wu, PK | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Accardo, G; Avenia, N; Castaldo, F; Colantuoni, V; Conzo, G; Di Donna, C; Esposito, D; Gambardella, C; Giugliano, D; Mazzella, M; Pasquali, D; Polistena, A | 1 |
| Hedayati, M; Rajabi, S | 1 |
| Bracho, O; Burns, SS; Chang, LS; Copik, AJ; Dinh, CT; Fernandez-Valle, C; Franco, MC; Fuse, MA; Liu, XZ; Mittal, R; Plati, SK; Shen, R; Soulakova, JN; Telischi, FF; Yan, D | 1 |
| Hadoux, J; Schlumberger, M | 1 |
| Droeser, R; Kouraklis, G; Patsouris, E; Tampaki, EC; Tampakis, A | 1 |
| Goto, K; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Maeda, Y; Makimoto, G; Matsumoto, S; Ninomiya, K; Ninomiya, T; Ohashi, K; Sato, A; Tabata, M; Tomida, S; Toyooka, S; Umemura, S; Watanabe, H | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Ali, SM; Chung, JH; DiClemente, F; Dolfi, SC; Ganesan, S; Gay, LM; Hirshfield, KM; Kulkarni, A; Lee, E; Leyland-Jones, B; Lin, S; Liu, C; Paratala, BS; Petrosky, W; Pham, K; Rodriguez-Rodriguez, L; Ross, JS; Schrock, AB; Williams, CB; Williams, K; Yao, M; Yilmazel, B | 1 |
| Balasubramanian, S; Carroll, C; Hamilton, J; Kaltenthaler, E; Moss, L; Tappenden, P; Wadsley, J; Wong, R | 1 |
| Adam, V; Arlt, VM; Heger, Z; Indra, R; Kolarik, M; Kopeckova, K; Stiborova, M | 1 |
| Ayaz, M; Bryant, AT; Ctortecka, C; Eschrich, SA; Fang, B; Haura, EB; Hu, Q; Kinose, F; Koomen, JM; Lawrence, HR; Remsing Rix, LL; Rix, U; Sumi, NJ; Welsh, EA | 1 |
| Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J | 1 |
| Adam, P; Allelein, S; Berg, E; Frank-Raue, K; Hoster, E; Koehler, VF; Kroiss, M; Raue, F; Schott, M; Spitzweg, C | 1 |
| Borghi, MO; Cantone, MC; Carra, S; Dicitore, A; Gaudenzi, G; Ghilardi, A; Hofland, LJ; Persani, L; Plebani, A; Saronni, D; Vitale, G | 1 |
| Courtier, B; Hadoux, J | 1 |
| Koehler, VF; Kroiss, M; Spitzweg, C | 1 |
| Bardet, S; Brose, MS; Capdevila, J; Elisei, R; Führer, D; Gao, M; Hadoux, J; Hoff, AO; Hu, MI; Isaev, P; Jarzab, B; Keam, B; Kopeckova, K; Lin, B; Lin, Y; Maeda, P; Robinson, BG; Sherman, EJ; Singh, R; Soldatenkova, V; Tahara, M; Wadsley, J; Wirth, LJ; Wright, J | 1 |
16 review(s) available for quinazolines and cabozantinib
| Article | Year |
|---|---|
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
Novel therapies for thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Clinical Trials as Topic; Diarrhea; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2014 |
Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.
Topics: Anilides; Antineoplastic Agents; Drug Monitoring; Evidence-Based Medicine; Humans; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Management of advanced medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Biomarkers; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Treatment Outcome | 2016 |
Systemic treatment and management approaches for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Genotype; Humans; Molecular Targeted Therapy; Phenotype; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptors, Fibroblast Growth Factor; Thyroid Neoplasms; Thyroidectomy; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Genetics of medullary thyroid cancer: An overview.
Topics: Anilides; Carcinoma, Medullary; Codon; Exons; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 2a; Mutation; Piperidines; Polymorphism, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; High-Throughput Nucleotide Sequencing; Humans; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cost-Benefit Analysis; England; Humans; Models, Economic; Piperidines; Pyridines; Quality-Adjusted Life Years; Quinazolines; Technology Assessment, Biomedical; Thyroid Neoplasms | 2019 |
1 trial(s) available for quinazolines and cabozantinib
| Article | Year |
|---|---|
Phase 3 Trial of Selpercatinib in Advanced
Topics: Antineoplastic Agents; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2023 |
20 other study(ies) available for quinazolines and cabozantinib
| Article | Year |
|---|---|
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
Topics: Anilides; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2013 |
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
Topics: Anilides; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Humans; Male; Middle Aged; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2014 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Everolimus; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methionine; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; Threonine; Thyroid Neoplasms | 2016 |
The Different Effects of VEGFA121 and VEGFA165 on Regulating Angiogenesis Depend on Phosphorylation Sites of VEGFR2.
Topics: Anilides; Animals; Colitis, Ulcerative; Colon; Intestinal Mucosa; Neovascularization, Pathologic; Phosphorylation; Protein Isoforms; Pyridines; Quinazolines; Rats; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Mitochondrial Dynamics; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2017 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Topics: Anilides; Animals; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dasatinib; Humans; Mice; Neurilemmoma; Neurofibromin 2; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Schwann Cells; src-Family Kinases; Xenograft Model Antitumor Assays | 2017 |
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.
Topics: Anilides; Humans; Mitochondria; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2018 |
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Topics: Anilides; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Sodium-Phosphate Cotransporter Proteins, Type IIb; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
RET rearrangements are actionable alterations in breast cancer.
Topics: Anilides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; NIH 3T3 Cells; Nuclear Receptor Coactivators; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; ras Guanine Nucleotide Exchange Factors; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Topics: Anilides; Animals; Cytochrome P-450 Enzyme Inhibitors; Ellipticines; Humans; Microsomes, Liver; Oxidation-Reduction; Peroxidases; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Quinolines; Rats | 2019 |
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase B; Cell Line, Tumor; Drug Discovery; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Organophosphates; Polypharmacology; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Quinolines; Systems Analysis | 2019 |
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Chemoradiotherapy; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Germany; Humans; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinazolines; Registries; Retrospective Studies; Thyroid Neoplasms; Time Factors; Young Adult | 2021 |
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Topics: Angiogenesis Inhibitors; Anilides; Animals; Apoptosis; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Embryo, Nonmammalian; Humans; Neovascularization, Pathologic; Neovascularization, Physiologic; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms; Zebrafish | 2021 |
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Medullary; Drug Approval; Humans; Mutation; Phenylurea Compounds; Piperidines; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Quinolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2021 |
[Medullary thyroid carcinoma: current clinical progress].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2021 |